JP3839343B2 - 選択的ｐｄｅ１０阻害剤の治療的使用 - Google Patents

選択的ｐｄｅ１０阻害剤の治療的使用 Download PDF

Info

Publication number
JP3839343B2
JP3839343B2 JP2002117635A JP2002117635A JP3839343B2 JP 3839343 B2 JP3839343 B2 JP 3839343B2 JP 2002117635 A JP2002117635 A JP 2002117635A JP 2002117635 A JP2002117635 A JP 2002117635A JP 3839343 B2 JP3839343 B2 JP 3839343B2
Authority
JP
Japan
Prior art keywords
pde10
papaverine
disorder
concentration
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002117635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002363103A (ja
Inventor
ロレイン・アン・レベル
フランク・サミュエル・メンニティ
クリストファー・ジョセフ・シュミット
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23092939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3839343(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2002363103A publication Critical patent/JP2002363103A/ja
Application granted granted Critical
Publication of JP3839343B2 publication Critical patent/JP3839343B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002117635A 2001-04-20 2002-04-19 選択的ｐｄｅ１０阻害剤の治療的使用 Expired - Fee Related JP3839343B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28514801P 2001-04-20 2001-04-20
US60/285148 2001-04-20

Publications (2)

Publication Number Publication Date
JP2002363103A JP2002363103A (ja) 2002-12-18
JP3839343B2 true JP3839343B2 (ja) 2006-11-01

Family

ID=23092939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002117635A Expired - Fee Related JP3839343B2 (ja) 2001-04-20 2002-04-19 選択的ｐｄｅ１０阻害剤の治療的使用

Country Status (13)

Country Link
US (1) US20030008806A1 (cg-RX-API-DMAC10.html)
EP (1) EP1250923A3 (cg-RX-API-DMAC10.html)
JP (1) JP3839343B2 (cg-RX-API-DMAC10.html)
KR (2) KR20020082136A (cg-RX-API-DMAC10.html)
CN (2) CN1382490A (cg-RX-API-DMAC10.html)
AU (1) AU3440902A (cg-RX-API-DMAC10.html)
CA (1) CA2382326A1 (cg-RX-API-DMAC10.html)
HK (1) HK1048070A1 (cg-RX-API-DMAC10.html)
HU (1) HUP0201310A3 (cg-RX-API-DMAC10.html)
IL (1) IL149106A0 (cg-RX-API-DMAC10.html)
NZ (1) NZ518478A (cg-RX-API-DMAC10.html)
PL (1) PL353535A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200203123B (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2004042391A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
AU2003291418A1 (en) * 2002-11-15 2004-06-15 Merck And Co., Inc. Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
DE602004028827D1 (de) * 2003-06-30 2010-10-07 Nycomed Gmbh Pyrrolodihydroisochinoline als pde10- inhibitoren
EP1641457B1 (en) * 2003-06-30 2009-08-05 Nycomed GmbH Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
MXPA06014236A (es) * 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
EP1838707B1 (en) * 2005-01-12 2009-04-29 Nycomed GmbH Novel pyrrolodihydroisoquinolines as pde10 inhibitors
AU2006279548A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
JPWO2008026687A1 (ja) 2006-09-01 2010-01-21 杏林製薬株式会社 ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤
EP2060572A4 (en) 2006-09-06 2010-11-17 Kyorin Seiyaku Kk PYRAZOLOPYRIDINE DERIVATIVE AND THIS ACTIVE PHOSPHODIESTERASE (PDE) INHIBITOR
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
EP2348018A4 (en) * 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
JPWO2010041711A1 (ja) 2008-10-09 2012-03-08 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
BR112012021198B1 (pt) 2010-02-26 2021-12-14 Mitsubishi Tanabe Pharma Corporation Compostos de pirazolopirimidina, composições relacionadas e seu uso como inibidores de pde10
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2014221799B2 (en) 2013-02-27 2017-09-28 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
JP3276762B2 (ja) * 1993-12-28 2002-04-22 日本臓器製薬株式会社 イソキノリン誘導体を含有する医薬組成物
HUT71408A (en) * 1994-01-14 1995-11-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission
CA2187086A1 (en) * 1994-04-15 1995-10-26 Masaomi Iyo A pharmaceutical composition for therapeutically treating tardive dyskinesia and uses therof
AU2252297A (en) * 1996-01-31 1997-08-22 Technology Licensing Co., L.L.C. Method of diagnosis and treatment and related compositions and apparatus
KR0177295B1 (ko) * 1996-02-28 1999-03-20 정명식 이소퀴놀린 화합물을 함유하는 항우울제
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
CA2321224A1 (en) * 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
WO2001032170A1 (en) * 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物

Also Published As

Publication number Publication date
US20030008806A1 (en) 2003-01-09
HUP0201310A2 (hu) 2003-02-28
AU3440902A (en) 2002-10-24
CN1382490A (zh) 2002-12-04
NZ518478A (en) 2004-04-30
EP1250923A2 (en) 2002-10-23
HK1048070A1 (zh) 2003-03-21
EP1250923A3 (en) 2003-01-15
HU0201310D0 (cg-RX-API-DMAC10.html) 2002-06-29
ZA200203123B (en) 2003-10-20
KR20020082136A (ko) 2002-10-30
CA2382326A1 (en) 2002-10-20
JP2002363103A (ja) 2002-12-18
PL353535A1 (en) 2002-10-21
CN1840181A (zh) 2006-10-04
IL149106A0 (en) 2002-11-10
KR20060002003A (ko) 2006-01-06
HUP0201310A3 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
JP3839343B2 (ja) 選択的ｐｄｅ１０阻害剤の治療的使用
RU2303259C2 (ru) Терапевтическое применение селективных ингибиторов pde10
Zhang et al. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats
Kehler et al. PDE10A inhibitors: novel therapeutic drugs for schizophrenia
Yeomans Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia
Schuckit Vulnerability factors for alcoholism
Li et al. Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia
WO2008036294A2 (en) Nos inhibitors for treatment of motor deficit disorders
US20040162293A1 (en) Therapeutic use of selective PDE10 inhibitors
EP1666886A2 (en) Method of identifying selective PDE10 inhibitor compounds
Kolodziej et al. Endogenous opioids inhibit ischemia‐induced generation of immature hippocampal neurons via the µ‐opioid receptor
Gross-Isseroff et al. Unaltered α2-noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysis
AU2007200574A1 (en) Therapeutic use of selective PDE10 inhibitors
HK1091746A (en) Therapeutic use of selective pde10 inhibitors
Siuciak et al. Treating neuropsychiatric disorders with PDE10A inhibitors
ZA200407823B (en) Therapeutic use of selective PDE10 inhibitors
Charych et al. Molecular And Cellular Understanding of PDE10A: A Dual‐Substrate Phosphodiesterase with Therapeutic Potential to Modulate Basal Ganglia Function
US20040023312A1 (en) Method for diagnosing huntingtons disease and means of treating it
Oda et al. Immunolocalization of muscarinic receptor subtypes in the reticular thalamic nucleus of rats
HK1077331A (en) Therapeutic use of selective pde10 inhibitors
Kim et al. Chronic ethanol exposure potentiates muscarinic receptor and α2-adrenoceptor-mediated inhibition of cAMP accumulation in PC 12 cells
Matos In Vitro Assessment of the Effects of Heroin on Telomere Length
Zhang Neuropsychopharmacological Effects of Selective Inhibitors of Subtypes of Phosphodiesterase-4 in Mice

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060802

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees